MRK · Insider Trading
Merck & Co., Inc.
Every open-market purchase and sale reported by MRK officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-01 | Mary Ellen Coe | Director | A | — | — |
| 2026-10-01 | Christine E Seidman | Director | A | — | — |
| 2026-10-01 | Surendralal Lanca Karsanbhai | Director | A | — | — |
| 2026-08-13 | Jennifer Zachary | EVP, General Counsel | MIXED | −25,388 | −$4.69M |
| 2026-08-13 | Chirfi Guindo | EVP, Access, Policy & Comms | Sell | −10,000 | −$1.35M |
| 2026-08-12 | Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | Sell | −45,320 | −$5.94M |
| 2026-08-10 | Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | Sell | −6,050 | −$788.77K |
| 2026-08-07 | David R. Maraldo | EVP & Pres. MMD | MIXED | — | −$869.30K |
| 2026-08-07 | Chirfi Guindo | EVP, Access, Policy & Comms | Sell | −15,000 | −$1.97M |
| 2026-08-07 | David Michael Williams | EVP,Chief Info&Digital Officer | MIXED | — | −$2.87M |
| 2026-08-07 | Chirfi Guindo | EVP, Access, Policy & Comms | Sell | −15,000 | −$1.97M |
| 2026-08-07 | David R. Maraldo | EVP & Pres. MMD | MIXED | — | −$869.30K |
| 2026-08-07 | David Michael Williams | EVP,Chief Info&Digital Officer | MIXED | — | −$2.87M |
| 2026-07-01 | Surendralal Lanca Karsanbhai | Director | A | — | — |
| 2026-07-01 | Mary Ellen Coe | Director | A | — | — |
| 2026-07-01 | Christine E Seidman | Director | A | — | — |
| 2026-06-02 | Douglas M Baker Jr | Director | A | — | — |
| 2026-06-02 | Pamela J. Craig | Director | A | — | — |
| 2026-06-02 | Thomas H Glocer | Director | A | — | — |
| 2026-06-02 | Risa J Lavizzo-Mourey | Director | A | — | — |
| 2026-06-02 | Stephen Mayo | Director | A | — | — |
| 2026-06-02 | Paul Rothman | Director | A | — | — |
| 2026-06-02 | Patricia F Russo | Director | A | — | — |
| 2026-06-02 | Christine E Seidman | Director | A | — | — |
| 2026-06-02 | Inge G Thulin | Director | A | — | — |
| 2026-06-02 | Mary Ellen Coe | Director | A | — | — |
| 2026-06-02 | Surendralal Lanca Karsanbhai | Director | A | — | — |
| 2026-06-02 | Kathy J Warden | Director | A | — | — |
| 2026-05-07 | Chirfi Guindo | EVP, Access, Policy & Comms | A | — | — |
| 2026-05-07 | Dalton E. Smart III | SVP Fin. - Global Controller | A | — | — |
| 2026-05-07 | Johannes Jacobus Oosthuizen | EVP, Oncology & Int?l | A | — | — |
| 2026-05-07 | David R. Maraldo | EVP & Pres. MMD | A | — | — |
| 2026-05-07 | Brian Foard | EVP, Specialty, Pharma, & ID | A | +77,000 deriv. | — |
| 2026-05-07 | Robert M Davis | Chairman, CEO & President | A | — | — |
| 2026-05-07 | Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | A | — | — |
| 2026-05-07 | Betty D Larson | EVP, Chief HR Officer | A | — | — |
| 2026-05-07 | Dean Y Li | Executive VP & President, MRL | A | — | — |
| 2026-05-07 | Caroline Litchfield | EVP & CFO | A | — | — |
| 2026-05-07 | David Michael Williams | EVP,Chief Info&Digital Officer | A | — | — |
| 2026-05-07 | Jennifer Zachary | EVP, General Counsel | A | — | — |
| 2026-05-05 | David R. Maraldo | EVP & Pres. MMD | MIXED | +393 | +$44.08K |
| 2026-05-05 | Dalton E. Smart III | SVP Fin. - Global Controller | MIXED | +251 | +$28.15K |
| 2026-05-01 | Johannes Jacobus Oosthuizen | EVP, Oncology & Int?l | MIXED | +698 | +$76.80K |
| 2026-05-01 | Robert M Davis | Chairman, CEO & President | MIXED | +6,749 | +$742.59K |
| 2026-05-01 | Caroline Litchfield | EVP & CFO | MIXED | +1,997 | +$219.73K |
| 2026-05-01 | Betty D Larson | EVP, Chief HR Officer | MIXED | +7,577 | +$839.41K |
| 2026-05-01 | Jennifer Zachary | EVP, General Counsel | MIXED | +1,497 | +$164.71K |
| 2026-05-01 | Dean Y Li | Executive VP & President, MRL | MIXED | +2,396 | +$263.63K |
| 2026-05-01 | Dalton E. Smart III | SVP Fin. - Global Controller | MIXED | +925 | +$102.06K |
| 2026-05-01 | David Michael Williams | EVP,Chief Info&Digital Officer | MIXED | +698 | +$76.80K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Robert M Davis | Chairman, CEO & President | 450,350 | $65.42M |
| Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | 111,488 | $16.20M |
| Dean Y Li | Executive VP & President, MRL | 94,431 | $13.72M |
| Caroline Litchfield | EVP & CFO | 92,300 | $13.41M |
| Sanat Chattopadhyay | Exe V-P & Pres. MMD | 68,764 | $9.99M |
| Jennifer Zachary | EVP, General Counsel | 45,509 | $6.61M |
| Chirfi Guindo | EVP, Access, Policy & Comms | 36,670 | $5.33M |
| David R. Maraldo | EVP & Pres. MMD | 36,280 | $5.27M |
| David Michael Williams | EVP,Chief Info&Digital Officer | 31,716 | $4.61M |
| Joseph Romanelli | President, Human Health Int?l | 28,739 | $4.17M |
| Johannes Jacobus Oosthuizen | EVP, Oncology & Int?l | 21,895 | $3.18M |
| Douglas M Baker Jr | Director | 16,000 | $2.32M |
| Betty D Larson | EVP, Chief HR Officer | 13,774 | $2.00M |
| Patricia F Russo | Director | 13,148 | $1.91M |
| Dalton E. Smart III | SVP Fin. - Global Controller | 9,388 | $1.36M |
| Thomas H Glocer | Director | 5,100 | $740.88K |
| Inge G Thulin | Director | 2,932 | $426.06K |
| Pamela J. Craig | Director | 1,715 | $249.14K |
| Risa J Lavizzo-Mourey | Director | 1,000 | $145.27K |
| Kathy J Warden | Director | 500 | $72.64K |
| Christine E Seidman | Director | 100 | $14.53K |
| Paul Rothman | Director | 100 | $14.53K |
| Stephen Mayo | Director | 100 | $14.53K |
| Mary Ellen Coe | Director | 10 | $1.45K |
| Surendralal Lanca Karsanbhai | Director | 1 | $145 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MRK quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.